You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
After more than 1000 failures, we know that our methods for translating effective stroke treatments from the laboratory to the clinic do not work. New preclinical and clinical approaches conceived outside of the current paradigm exist and should be carefully considered. Now, Tymianski and colleagues report on results obtained during translation of a new neuroprotectant.
- Copyright © 2012, American Association for the Advancement of Science
